Aims: Prostate cancer is a significant health concern worldwide, and early detection is crucial for effective treatment. This study aimed to investigate the role of the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) score in detecting prostate cancer in patients undergoing Transurethral Resection of the Prostate (TURP). Additionally, comprehensive analysis was performed to explore clinical parameters associated with incidentally diagnosed prostate cancer post-TURP. Methods: A total of 131 patients with symptomatic bladder outlet obstruction who underwent TURP were included in the study. The patients were divided into two groups: those with benign prostatic hyperplasia (BPH) and those with invasive prostatic carcinoma. The IPC group consisted of patients with both low-grade and high-grade IPC determined by Gleason score. Demographic data, including age, race, medical history, body mass index, smoking and alcohol status, and family history of prostate cancer, were evaluated. Postoperative measurement of specimen weight and prostate-specific antigen (PSA) levels were also analyzed. Result: Results revealed that approximately 50% of patients had BPH, while the remaining 50% had IPC. Patients with IPC, particularly high-grade IPC, had significantly higher PSA levels and lower resected specimen weight compared to those with BPH. The HALP score, which incorporates hemoglobin, albumin, lymphocyte, and platelet levels, showed promise as a discriminatory tool for distinguishing between BPH and IPC, as well as between high-grade IPC and BPH/low-grade IPC. Logistic regression analysis identified increased PSA levels, decreased HALP score, and smaller specimen weight as independent predictive factors for IPC after TURP. Notably, HALP score was the only significant independent predictive factor associated with high-grade IPC.  Conclusion: These findings contribute to the understanding of risk factors and diagnostic tools for incidentally detected prostate cancer in patients with bladder outlet obstruction undergoing TURP. The HALP score, along with PSA levels and specimen weight, can aid in the early detection and management of prostate cancer. Further research is warranted to validate these findings and explore the clinical utility of the HALP score in predicting prostate cancer outcomes.

The authors have declared no competing interest.

This research received no external funding.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

I confirm that all relevant ethical guidelines have been followed, and any necessary IRB (Institutional Review Board) and/or ethics committee approvals have been obtained (the Feinstein Institutes for Medical Research/Northwell Health system located in New York City, USA). Ethical approval was waived; IRB approval number: 23-0717.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data and materials are available upon request from the corresponding author